


Stereochemistry abstracts

Leandro Piovan, Marina Capelari, Leandro H. Andrade,
João V. Comasseto and André L. M. Porto*

Tetrahedron: Asymmetry 18 (2007) 1398



C₁₂H₁₆SeO
trans-(1*S*,2*S*)-2-(Phenylseleno)cyclohexanol


Ee = 99%

$[\alpha]_D^{25} = +44.8$ (*c* 0.53, CHCl₃)

Absolute configuration: (S,S)

Leandro Piovan, Marina Capelari, Leandro H. Andrade,
João V. Comasseto and André L. M. Porto*

Tetrahedron: Asymmetry 18 (2007) 1398



C₁₂H₁₆SeO
cis-(1*S*,2*S*)-2-(Phenylseleno)cyclohexanol

Ee = 99%


$[\alpha]_D^{25} = +10.1$ (*c* 0.42, CHCl₃)

Absolute configuration: (R,S)

Antti Hartikka, Adam T. Ślósarczyk and Per I. Arvidsson*

Tetrahedron: Asymmetry 18 (2007) 1403

$[\alpha]_D^{23} = +5.5$ (*c* 1.0, MeOH)




C₁₅H₁₃N₃O₅S
(*S*)-*N*-[(4-Nitrophenyl)sulfonyl]indoline-2-carboxamide


Antti Hartikka, Adam T. Ślósarczyk and Per I. Arvidsson*

Tetrahedron: Asymmetry 18 (2007) 1403

$[\alpha]_D^{23} = -5.4$ (*c* 1.0, MeOH)




C₁₆H₁₆N₂O₃S
(*S*)-*N*-[(4-Methylphenyl)sulfonyl]indoline-2-carboxamide



C₂₄H₃₂N₂O₃S
(*S*)-*N*-[(2,4,6-Triisopropylphenyl)sulfonyl]indoline-2-carboxamide

[α]_D²³ = -47.2 (*c* 1.0, MeOH)




C₂₆H₂₇NO₂
Methyl 2-{(S)-[N-benzyl-N-((S)-1-phenylethyl)amino]phenylmethyl}acrylate

Ee >97%, de >95% (NMR)

[α]_D²¹ = +88.7 (*c* 0.13, CHCl₃)

Source of chirality: asymmetric synthesis




C₄₁H₄₄N₂O₂
Methyl (R)-3-[N-benzyl-N-((S)-1-phenylethyl)amino]-2-{[N-benzyl-N-((S)-1-phenylethyl)amino]methyl}-3-phenylpropionate [faster eluting diastereomer (silica gel, *n*-pentane-Et₂O 10:1)]

Ee >97%, de >95% (NMR)

[α]_D²² = -102.2 (*c* 0.14, CHCl₃)

Source of chirality: asymmetric synthesis




C₄₁H₄₄N₂O₂
Methyl (R)-3-[N-benzyl-N-((S)-1-phenylethyl)amino]-2-{[N-benzyl-N-((S)-1-phenylethyl)amino]methyl}-3-phenylpropionate [slower eluting diastereomer (silica gel, *n*-pentane-Et₂O 10:1)]

Ee >97%, de >95% (NMR)

[α]_D²² = +25.9 (*c* 0.10, CHCl₃)


Source of chirality: asymmetric synthesis

(2*S*,4*S*)-2,4-Bis[(*R*)-phenyl-((*S*)-1-phenylethylamino)methyl]pentane-1,5-diol

Ee >97%, de >95% (NMR)

 $[\alpha]_D^{21} = -125.5$ (*c* 0.06, CHCl₃)


Source of chirality: asymmetric synthesis

(1*S*,4*R*,5*S*,8*R*)-4,8-Diphenyl-3,7-bis((*S*)-1-phenylethyl)-3,7-diazabicyclo[3.3.1]nonane-2,6-dione

Ee >97%, de >95% (NMR)

 $[\alpha]_D^{21} = +15.7$ (*c* 0.10, CHCl₃)


Source of chirality: asymmetric synthesis

(1*R*,2*R*,5*R*,6*R*)-2,6-Diphenyl-3,7-bis((*S*)-1-phenylethyl)-3,7-diazabicyclo[3.3.1]nonane

Ee >97%, de >95% (NMR)

 $[\alpha]_D^{21} = -5.5$ (*c* 0.10, CHCl₃)


Source of chirality: asymmetric synthesis

(2*R*,4*R*)-2,4-Dibenzyl-N,N'-bis((*S*)-1-phenylethyl)-pentane-1,5-diamine

Ee >97%, de >95% (NMR)


 $[\alpha]_D^{22} = +26.9$ (*c* 0.10, CHCl₃)

Source of chirality: asymmetric synthesis




Ee >97%, de >95% (NMR)
 $[\alpha]_D^{21} = +9.8$ (*c* 0.13, CHCl₃)
 Source of chirality: asymmetric synthesis

Dimethyl (2*S*,4*S*)-2,4-bis{(R)-[N-benzyl-N-((S)-1-phenylethyl)amino]phenylmethyl}glutarate




Ee >97%, de >95% (NMR)
 $[\alpha]_D^{21} = +29.9$ (*c* 0.14, CHCl₃)
 Source of chirality: asymmetric synthesis

Dimethyl (2*S*,4*R*)-2,4-bis{(R)-[N-benzyl-N-((S)-1-phenylethyl)amino]phenylmethyl}glutarate



Ee >97%, de >95% (NMR)
 $[\alpha]_D^{19} = -40.3$ (*c* 0.18, CHCl₃)
 Source of chirality: asymmetric synthesis

Dimethyl (2*S*,4*S*)-2,4-bis[(R)-phenyl-((S)-1-phenylethylamino)methyl]glutarate





$[\alpha]_D = +10.5$ (*c* 1.8, CHCl₃)
 Source of chirality: L-(+)-tartaric acid
 Absolute configuration: (4*R*,5*R*)

(4*R*,5*R*)-4,5-Bis(pent-4-enoyl)-2,2-dimethyl-1,3-dioxolane

$[\alpha]_D = +11.6 \text{ (c } 1.2, \text{ CHCl}_3\text{)}$

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4R,5R)





(4R,5R)-4,5-Bis(hex-5-enoyl)-2,2-dimethyl-1,3-dioxolane

 $[\alpha]_D = +10.0 \text{ (c } 1.0, \text{ CHCl}_3\text{)}$

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4R,5R)




(4R,5R)-4,5-Bis(hept-6-enoyl)-2,2-dimethyl-1,3-dioxolane

 $[\alpha]_D = -7.8 \text{ (c } 2.8, \text{ CHCl}_3\text{)}$

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4S,5S)





(4S,5S)-4,5-Bis((R)-1-hydroxypent-4-enyl)-2,2-dimethyl-1,3-dioxolane


 $[\alpha]_D = -7.5 \text{ (c } 1.1, \text{ CHCl}_3\text{)}$

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4S,5S)



(4S,5S)-4,5-Bis((R)-1-hydroxyhex-5-enyl)-2,2-dimethyl-1,3-dioxolane




(4S,5S)-4,5-Bis((R)-1-hydroxyhept-6-enyl)-2,2-dimethyl-1,3-dioxolane

 $[\alpha]_D = -8.6$ (*c* 3.0, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (4S,5S)




(5R,6R,7R,8R)-5,8-Bis(benzyloxy)dodeca-1,11-diene-6,7-diol

 $[\alpha]_D = -24.4$ (*c* 1.8, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (5R,6R,7R,8R)




(6R,7R,8R,9R)-6,9-Bis(benzyloxy)tetradeca-1,13-diene-7,8-diol

 $[\alpha]_D = -25.8$ (*c* 2.1, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (6R,7R,8R,9R)



(7R,8R,9R,10R)-7,10-Bis(benzyloxy)hexadeca-1,15-diene-8,9-diol

 $[\alpha]_D = -27.7$ (*c* 2.7, CHCl₃)


Source of chirality: L-(+)-tartaric acid

Absolute configuration: (7R,8R,9R,10R)

$[\alpha]_D = -10.8$ (*c* 3.5, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (2*R*)




(*R*)-2-(Benzylxy)hex-5-en-1-ol

$[\alpha]_D = -12.2$ (*c* 1.8, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (2*R*)





(*R*)-2-(Benzylxy)hept-6-en-1-ol

$[\alpha]_D = -14.7$ (*c* 1.9, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (2*R*)




(*R*)-2-(Benzylxy)oct-7-en-1-ol


$[\alpha]_D = +66.6$ (*c* 0.3, Et₂O)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (1*R*,5*S*,7*R*)



(+)-*exo*-Brevicomine: (1*R*,5*S*,7*R*)-7-ethyl-5-methyl-6,8-dioxabicyclo[3.2.1]octane




$C_{15}H_{22}O_2$
(*2R,3R*)-3-(Benzylxy)oct-7-en-2-ol

$[\alpha]_D = -24.3$ (*c* 1.1, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (2*R*,3*R*)




$C_{22}H_{30}O_3$
(*7R,8R*)-7,8-Bis(benzylxy)nonan-3-one

$[\alpha]_D = +9.1$ (*c* 3.2, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (7*R*,8*R*)




$C_9H_{16}O_2$
iso-exo-Brevicomin: (1*R*,5*S*,7*R*)-5-ethyl-7-methyl-6,8-dioxabicyclo[3.2.1]octane

$[\alpha]_D = +54.0$ (*c* 0.5, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (1*R*,5*S*,7*R*)




$C_{22}H_{36}O_4$
(*R*)-2-(Benzylxy)-1-(methoxymethoxy)tridecan-7-one

$[\alpha]_D = +13.7$ (*c* 1.6, CHCl₃)

Source of chirality: L-(+)-tartaric acid


Absolute configuration: (2*R*)

 $C_{15}H_{30}O_4$


(R)-2-(Hydroxy)-1-(methoxymethoxy)tridecan-7-one

 $[\alpha]_D = +15.0$ (*c* 1.4, CHCl₃)

Source of chirality: L-(+)-tartaric acid

Absolute configuration: (2*R*) $C_{13}H_{26}O_2$ (2*R*,7*R*)-7-Hexyl-2-(hydroxymethyl)oxepane $[\alpha]_D = +6.6$ (*c* 1.8, MeOH)

Source of chirality: L-(+)-tartaric acid


Absolute configuration: (2*R*,7*R*) $C_{10}H_{11}NO_2$

(R)-1,2,3,4-Tetrahydroisoquinoline-1-carboxylic acid

Ee = 96%

 $[\alpha]_D^{25} = -63.1$ (*c* 1, 1 mol dm⁻³ HCl) $[\alpha]_D^{25} = +18.8$ (*c* 2, 1 mol dm⁻³ NaOH)Source of chirality: enzyme-catalyzed resolution with lipase B from *Candida antarctica*

Absolute configuration: (R)


 $C_{18}H_{18}N_4O_9$

(S)-1-(Ethoxycarbonyl)-1,2,3,4-tetrahydroisoquinolinium 2,4,6-trinitrophenolate

Ee = 92%

 $[\alpha]_D^{25} = -28.2$ (*c* 0.5, CHCl₃) $[\alpha]_D^{25} = -30.2$ (*c* 0.5, toluene)Source of chirality: enzyme-catalyzed resolution with lipase B from *Candida antarctica*

Absolute configuration: (S)

 $C_{20}H_{19}NO_3$


(R)-3-((E)-4-Phenylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{25} = -85.9$ (*c* 1.6, CH_2Cl_2)

Source of chirality: enantiomerically pure starting material

Absolute configuration: (R)


 $C_{21}H_{21}NO_3$

(R)-3-((R,E)-2-Methyl-4-phenylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -149.0$ (*c* 0.96, CH_2Cl_2)

Source of chirality: diastereoselective alkylation

Absolute configuration: (2*R*,3*R*) $C_{12}H_{14}O_2$


(R,E)-2-Methyl-4-phenylpent-3-enoic acid

Ee = 100%

 $[\alpha]_D^{20} = -53.1$ (*c* 1.15, CH_2Cl_2)

Source of chirality: enantiomerically pure starting material

Absolute configuration: (R)


 $C_{12}H_{13}IO_2$ (3*S*,4*R*,5*S*)-Dihydro-4-iodo-3,5-dimethyl-5-phenylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = -45.9$ (*c* 0.90, CH_2Cl_2)

Source of chirality: diastereospecific iodo lactonization

Absolute configuration: (3*S*,4*R*,5*S*)




(R,E)-2-Benzyl-4-phenylpent-3-enoic acid

Ee = 100%

 $[\alpha]_D^{20} = -154.1$ (*c* 1.08, CH₂Cl₂)

Source of chirality: enantiomerically pure starting material

Absolute configuration: (R)




(R)-3-((Z)-4-Phenylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -30.7$ (*c* 1.2, CH₂Cl₂)

Source of chirality: enantiomerically pure starting material

Absolute configuration: (R)





(R,Z)-2-Methyl-4-phenylpent-3-enoic acid

Ee = 100%

 $[\alpha]_D^{20} = -252.8$ (*c* 1.2, CH₂Cl₂)

Source of chirality: diastereoselective alkylation

Absolute configuration: (2S,3R)



(3S,4R,5S)-4-Bromo-dihydro-3,5-dimethyl-5-phenylfuran-2(3H)-one

Ee = 100%

 $[\alpha]_D^{20} = -25.4$ (*c* 3, CH₂Cl₂)


Source of chirality: diastereospecific bromo lactonization

Absolute configuration: (3S,4R,5S)

Ee = 100%

 $[\alpha]_D^{20} = -66.3$ (*c* 0.9, CH₂Cl₂)


Source of chirality: diastereospecific iodo lactonization

Absolute configuration: (3*S*,4*R*,5*R*)(3*S*,4*R*,5*R*)-Dihydro-4-iodo-3,5-dimethyl-5-phenylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = -196.8$ (*c* 1.33, CH₂Cl₂)

Source of chirality: diastereoselective alkylation


Absolute configuration: (2*R*,3*R*)

(R)-3-((R,E)-2-Benzyl-4-phenylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -54.8$ (*c* 1.98, CH₂Cl₂)

Source of chirality: enantiomerically pure starting material


Absolute configuration: (*R*)

(R,E)-4-Phenyl-2-propylpent-3-enoic acid

Ee = 100%

 $[\alpha]_D^{20} = -11.0$ (*c* 1.07, CH₂Cl₂)


Source of chirality: diastereospecific bromo lactonization

Absolute configuration: (3*S*,4*R*,5*S*)(3*S*,4*R*,5*S*)-3-Benzyl-4-bromo-dihydro-5-methyl-5-phenylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = +4.2$ (*c* 1.25, CH₂Cl₂)


Source of chirality: diastereospecific iodo lactonization

Absolute configuration: (3*S*,4*R*,5*S*)(3*S*,4*R*,5*S*)-3-Benzyl-4-iodo-dihydro-5-methyl-5-phenylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = -128.1$ (*c* 0.99, CH₂Cl₂)


Source of chirality: diastereoselective alkylation

Absolute configuration: (2*R*,3*R*)(R)-3-((*R,E*)-4-Phenyl-2-propylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -151.0$ (*c* 1.1, CH₂Cl₂)


Source of chirality: diastereoselective alkylation

Absolute configuration: (2*R*,3*R*)(R)-3-(2-((*E*)-2-Phenylprop-1-enyl)pent-4-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -18.9$ (*c* 0.75, CH₂Cl₂)


Source of chirality: diastereospecific iodo lactonization

Absolute configuration: (3*S*,4*R*,5*S*)(3*S*,4*R*,5*S*)-Dihydro-4-iodo-5-methyl-5-phenyl-3-propylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = -100.3$ (*c* 0.5, CH₂Cl₂)


Source of chirality: diastereoselective alkylation

Absolute configuration: (2*R*,3*R*)(R)-3-((*R,Z*)-2-Methyl-4-phenylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -80.2$ (*c* 2.1, CH₂Cl₂)


Source of chirality: enantiomerically pure starting material

Absolute configuration: (*R*)(R)-2-((*E*)-2-Phenylprop-1-enyl)pent-4-enoic acid

Ee = 100%

 $[\alpha]_D^{20} = -30.1$ (*c* 0.9, CH₂Cl₂)


Source of chirality: diastereospecific iodo lactonization

Absolute configuration: (3*S*,4*R*,5*S*)(3*S*,4*R*,5*S*)-3-Allyl-dihydro-4-iodo-5-methyl-5-phenylfuran-2(3*H*)-one


Ee = 100%

 $[\alpha]_D^{20} = -310.0$ (*c* 2.0, CH₂Cl₂)

Source of chirality: enantiomerically pure starting material

Absolute configuration: (*R*)

(R)-2,4-Dimethylpent-3-enoic acid


 $C_{16}H_{19}NO_3$

(R)-3-((R)-2,4-Dimethylpent-3-enoyl)-4-phenyloxazolidin-2-one

Ee = 100%

 $[\alpha]_D^{20} = -157.0$ (*c* 2.0, CH_2Cl_2)


Source of chirality: diastereoselective alkylation

Absolute configuration: (2*R*,3*R*) $C_7H_{12}O_3$ (3*R*,5*R*)-Dihydro-5-(hydroxymethyl)-3,5-dimethylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = -4.9$ (*c* 0.90, EtOH)


Source of chirality: enantiomerically pure starting material

Absolute configuration: (3*R*,5*R*) $C_7H_{11}IO_2$ (3*S*,4*R*)-Dihydro-4-iodo-3,5,5-trimethylfuran-2(3*H*)-one

Ee = 100%

 $[\alpha]_D^{20} = -16.7$ (*c* 2.0, CH_2Cl_2)

Source of chirality: diastereospecific iodo lactonization


Absolute configuration: (3*S*,4*R*) $C_{12}H_{14}O_2$ (3*R*,5*R*)-Dihydro-3,5-dimethyl-5-phenylfuran-2(3*H*)-one

Ee = 100%


 $[\alpha]_D^{20} = -32.0$ (*c* 0.33, CH_2Cl_2)

Source of chirality: enantiomerically pure starting material

Absolute configuration: (3*R*,5*R*)

(3*R*,5*S*)-Dihydro-3,5-dimethyl-5-(11-phenylundecyl)furan-2(3*H*)-one $Ee = 100\%$ $[\alpha]_D^{20} = -8.5 (c \ 0.2, \ MeOH)$


Source of chirality: enantiomerically pure starting material

Absolute configuration: (3*R*,5*S*)


(S)-2-[(2,6-Trifluoromethanebenzenesulfonyl)aminomethyl]pyrrolidine

 $[\alpha]_D^{20} = -10 (c \ 0.30, \ MeOH)$

Source of chirality: (S)-2-aminomethylpyrrolidine


Absolute configuration: (2*S*)(2*S*,5*R*,9*R*,12*S*,2'*R*,6'*S*)-5,9-Bis-*N*-(6'-ethoxy-2',3',4',5'-tetrahydro-5'-isopropyl-2'-methyl-3'-oxopyrazin-2'-yl-acetyl)-3,11-diaza-2,12-diisopropyl-4,10-dioxa-7-methyltridecane-1,13-dicarboxylic acid diethylester $[\alpha]_D = -28 (c \ 2.1, \ CHCl_3)$

Source of chirality: L-valine

Absolute configuration: (2*S*,5*R*,9*R*,12*S*,2'*R*,6'*S*)(2*S*,5*R*,9*R*,12*S*,2'*R*,6'*S*)-5,9-bis-*N*-(6'-ethoxy-2',3',4',5'-tetrahydro-5'-isopropyl-2'-methyl-3'-oxopyrazin-2'-yl-acetyl)-5,9-dimethyl-3,11-diaza-2,12-diisopropyl-4,10-dioxa-7-methyltridecane-1,13-dicarboxylic acid diethylester $[\alpha]_D = +10.2 (c \ 1, \ CHCl_3)$

Source of chirality: L-valine

Absolute configuration: (2*S*,5*R*,9*R*,12*S*,2'*R*,6'*S*)




$[\alpha]_D = +67$ (*c* 0.7, CHCl₃)

Source of chirality: L-valine

Absolute configuration: (2*S*,5*R*,9*R*,12*S*,3'*R*,6'*S*)

(2*S*,5*R*,9*R*,12*S*,3'*R*,6'*S*)-5,9-bis-*N*-(3'-methyl-6'-ethoxycarbonil-5'-aza-4'-oxa-3'-acetamido-octanoyl)-3,11-diaza-2,12-diisopropyl-4,10-dioxa-7-methyltridecane-1,13-dicarboxylic acid diethylester




$[\alpha]_D = -10.6$ (*c* 1.5, CHCl₃)

Source of chirality: L-valine

Absolute configuration: (2*S*,5*S*,9*S*,12*S*,2'*R*,6'*S*)

(2*S*,5*S*,9*S*,12*S*,2'*R*,6'*S*)-5,9-bis-*N*-(6'-ethoxy-2',3',4',5'-tetrahydro-5'-isopropyl-2'-methyl-3'-oxopyrazin-2'-yl-acetyl)-5,9-dimethyl-3,11-diaza-2,12-diisopropyl-4,10-dioxa-7-methyltridecane-1,13-dicarboxylic acid diethylester




$[\alpha]_D = +36.2$ (*c* 0.6, CHCl₃)

Source of chirality: L-valine

Absolute configuration: (2*S*,5*S*,9*S*,12*S*,3'*R*,6'*S*)

(2*S*,5*S*,9*S*,12*S*,3'*R*,6'*S*)-5,9-bis-*N*-(3'-methyl-6'-ethoxycarbonil-5'-aza-4'-oxa-3'-acetamido-octanoyl)-5,9-dimethyl-3,11-diaza-2,12-diisopropyl-4,10-dioxa-7-methyltridecane-1,13-dicarboxylic acid diethylester




$[\alpha]_D = +15.8$ (*c* 0.4, CHCl₃)

Source of chirality: L-valine

Absolute configuration: (2*S*,5*R*,9*R*,12*S*,3'*R*,6'*S*)

(2*S*,5*R*,9*R*,12*S*,3'*R*,6'*S*)-5,9-bis-*N*-(3'-methyl-6'-ethoxycarbonil-5'-aza-4'-oxa-3'-acetamido-octanoyl)-5,9-dimethyl-3,11-diaza-2,12-diisopropyl-4,10-dioxa-7-methyltridecane-1,13-dicarboxylic acid diethylester




C₉H₁₁NO₂
(R)-(+)-2-Nitro-1-phenylpropane

Ee = 98%

[α]_D³⁰ = +42.0 (c 1.91 CHCl₃)

Source of chirality: microbial reduction

Absolute configuration: (R)




C₉H₁₀ClNO₂
(R)-(+)-2-Nitro-1-(4-chlorophenyl)propane

Ee = 91%

[α]_D³¹ = +37.0 (c 2.11 CHCl₃)

Source of chirality: microbial reduction

Absolute configuration: (R)




C₁₀H₁₃NO₂
(R)-(+)-2-Nitro-1-(4-methylphenyl)propane

Ee = 97%

[α]_D²⁷ = +39.2 (c 2.01 CHCl₃)

Source of chirality: microbial reduction

Absolute configuration: (R)




C₁₀H₁₃NO₃
(R)-(+)-2-Nitro-1-(4-methoxyphenyl)propane

Ee = 99%

[α]_D²⁸ = +43.7 (c 1.02 CHCl₃)

Source of chirality: microbial reduction

Absolute configuration: (R)




$C_{14}H_{15}NO_3$
(-)-Ethyl 3-[(1R)-1-phenylethyl]isoxazole-5-carboxylate

Ee = 98%

$[\alpha]_D^{28} = -36.6$ (*c* 0.63 CHCl₃)

Source of chirality: chiral substrate

Absolute configuration: (*R*)




$C_{14}H_{14}ClNO_3$
(-)-Ethyl 3-[(1R)-1-(4-chlorophenyl)ethyl]isoxazole-5-carboxylate

Ee = 91%

$[\alpha]_D^{28} = -27.7$ (*c* 1.08 CHCl₃)

Source of chirality: chiral substrate

Absolute configuration: (*R*)




C_8H_9ClO
(*R*)-(-)-2-Chloro-1-phenylethanol

Ee = 95%

$[\alpha]_D^{23} = -51.4$ (*c* 1.02 CHCl₃)

Source of chirality: kinetic resolution

Absolute configuration: (*R*)




$C_4H_8O_2$
(*R*)-3-Hydroxy-butan-2-one

Ee >99%

$[\alpha]_D^{20} = -61.4$ (*c* 0.2, EtOH)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (*R*)



Ee >99%


$[\alpha]_D^{20} = +3.8$ (*c* 1.0, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (*R*)

C₈H₁₄O₂

(*R*)-3-Hydroxy-6-methyl-5-hepten-2-one



Ee >99%


$[\alpha]_D^{20} = -13.8$ (*c* 0.5, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (*R*)

C₈H₁₆O₂

(*R*)-5-Hydroxyoctan-4-one



Ee >99%


$[\alpha]_D^{20} = -49.3$ (*c* 1.8, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*)

C₁₃H₁₈O₃

(*R*)-1-Hydroxy-1-(4-*t*-butoxyphenyl)propan-2-one



Ee >99%


$[\alpha]_D^{20} = +72.8$ (*c* 1.0, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (*R*)

C₅H₉ClO₂

(*R*)-1-(3-Chlorophenyl)-2-hydroxypropan-1-one




C₉H₈F₂O₂
(R)-1-(3',5'-Difluorophenyl)-2-hydroxypropan-1-one

Ee >99%

[α]_D²⁰ = +50.0 (c 1.0, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)




C₉H₇O₂F₃
(S)-3,3,3-Trifluoro-2-hydroxy-1-phenylpropan-1-one

Ee >99%

[α]_D²⁰ = +8.6 (c 0.2, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (S)




C₁₀H₈O₄
(R)- α -Furoin

Ee >99%

[α]_D²⁰ = +62.7 (c 0.9, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)




C₁₂H₁₀N₂O₂
(R)- α -Pyridoin

Ee >99%

[α]_D²⁰ = +78.8 (c 0.8, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)




C₁₆H₁₆O₄
(R)-2,2'-Dimethoxybenzoin

Ee >99%

[α]_D²⁰ = -70.4 (c 1.0, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)




C₁₆H₁₆O₄
(R)-4,4'-Dimethoxybenzoin

Ee >99%

[α]_D²⁰ = -87.9 (c 1.3, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)




C₆H₁₀O₂
(R)-2-Hydroxycyclohexanone

Ee >99%

[α]_D²⁰ = +20.8 (c 0.65, CHCl₃)

Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)







C₉H₈O₃
(R)-2-Hydroxychroman-4-one


Ee = 82%

[α]_D²⁰ = +72.9 (c 0.82, CHCl₃)


Source of chirality: lipase catalyzed kinetic resolution

Absolute configuration: (R)


(1*R*,*S*)-1-Methoxycarbonylmethyl-3,8-dimethyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid benzyl ester $[\alpha]_D^{20} = +18.1$ (*c* 0.93, MeOH)Source of chirality: [1-(*S*)-methyl-2-bromo]ethyl carbamic acid benzyl esterAbsolute configuration: (1*R*,*S*)(1*S*,*R*)-3-Ethyl-1-methoxycarbonylmethyl-8-methyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid benzyl ester $[\alpha]_D^{20} = -0.8$ (*c* 1.16, MeOH)Source of chirality: [1-(*R*)-ethyl-2-bromo]ethyl carbamic acid benzyl esterAbsolute configuration: (1*S*,*R*)(1*R*,*S*)-3-Benzyl-1-methoxycarbonylmethyl-8-methyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid benzyl ester $[\alpha]_D^{20} = -40.9$ (*c* 1.00, MeOH)Source of chirality: [1-(*S*)-benzyl-2-bromo]ethyl carbamic acid benzyl esterAbsolute configuration: (1*R*,*S*)(1*R*,*S*)-3-Isobutyl-1-methoxycarbonylmethyl-8-methyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid benzyl ester $[\alpha]_D^{20} = +15.3$ (*c* 0.98, MeOH)Source of chirality: [1-(*S*)-*i*-Bu-2-bromo]ethyl carbamic acid benzyl esterAbsolute configuration: (1*R*,*S*)

 $C_{24}H_{29}NO_4$

(1S,3R)-3,8-Ethyl-1-methoxycarbonylmethyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid benzyl ester

 $[\alpha]_D^{20} = -9.8$ (*c* 1.0, MeOH)Source of chirality: [1-(*R*)-ethyl-2-bromo]ethyl carbamic acid benzyl esterAbsolute configuration: (1*S*,3*R*) $C_{25}H_{31}NO_4$

(1S,3R)-3-Ethyl-8-isopropyl-1-methoxycarbonylmethyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid benzyl ester


 $[\alpha]_D^{20} = -9.2$ (*c* 1.2, MeOH)Source of chirality: [1-(*R*)-ethyl-2-bromo]ethyl carbamic acid benzyl esterAbsolute configuration: (1*S*,3*R*) $C_{18}H_{24}O_4$

(R)-3-Isobutyl-pentanedioic acid mono-(3-phenyl-allyl) ester

Ee = 97%

 $[\alpha]_D^{25} = -0.53$ (neat)

Source of chirality: asymmetric synthesis

Absolute configuration: (*R*) $C_{27}H_{33}NO_4$


(S)-5-Methyl-3-[(3-phenyl-allyloxycarbonilamino)-methyl]-hexanoic acid 3-phenyl-allyl ester

Ee = 97%

 $[\alpha]_D^{25} = -4.3$ (*c* 20, EtOH)

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

 $Ee = 97\%$ $[\alpha]_D^{25} = -4.2 (c \text{ } 20, \text{ EtOH})$

Source of chirality: asymmetric synthesis

Absolute configuration: (S)




(S)-3-(Benzoyloxycarbonylamino-methyl)-5-methyl-hexanoic acid 3-phenyl-allyl ester


 $Ee = 97\%$ $[\alpha]_D^{25} = -4.4 (c \text{ } 25, \text{ EtOH})$

Source of chirality: asymmetric synthesis

Absolute configuration: (S)




(S)-3-(Benzoyloxycarbonylamino-methyl)-5-methyl-hexanoic acid


 $Ee = 99.7\%$ $[\alpha]_D^{25} = +10.8 (c \text{ } 1.1, \text{ H}_2\text{O})$

Source of chirality: asymmetric synthesis

Absolute configuration: (S)



(S)-3-Aminomethyl-5-methyl-hexanoic acid


 $[\alpha]_D^{22} = -442 (c \text{ } 0.052, \text{ CHCl}_3)$

Source of chirality: (1S,2S)-(+)-1,2-diaminocyclohexane

Absolute configuration: (1S,2S)

 $C_{14}H_{22}N_2O_4S_2$

(1S,2S)-N,N'-1,2-Cyclohexanediyl-bis-thioxoalamic acid diethyl ester




(1S,2S)-*N,N'*-1,2-Cyclohexanediyi-bis-oxalamic acid diethyl ester

$[\alpha]_D^{22} = -31$ (*c* 1.168, CHCl₃)

Source of chirality: (1*S*,2*S*)-(+)1,2-diaminocyclohexane

Absolute configuration: (1*S*,2*S*)




(1*R*,2*R*)-*N,N'*-1,2-Diphenylethanediyl-bis-oxalamic acid diethyl ester

$[\alpha]_D^{22} = -103.8$ (*c* 0.106, CHCl₃)

Source of chirality: (1*R*,2*R*)-(+)1,2-diphenylethylenediamine

Absolute configuration: (1*R*,2*R*)




(1*R*,2*R*)-*N,N'*-1,2-Diphenylethanediyl-bis-thioxoalamic acid diethyl ester

$[\alpha]_D^{22} = -155.6$ (*c* 0.045, CHCl₃)

Source of chirality: (1*R*,2*R*)-(+)1,2-diphenylethylenediamine

Absolute configuration: (1*R*,2*R*)




N,N'-Biphenyl-2,2'-diyl-bis-oxalamic acid dimethyl ester

$[\alpha]_D^{20} = -82.8$ (*c* 0.169, CHCl₃)

Source of chirality: (1*R*,2*S*,5*R*)-menthol

Absolute configuration: (1*R*,2*S*,5*R*)




N,N'-Biphenyl-2,2'-diyl-bis-thiooxalamic acid dimethyl ester

$[\alpha]_D^{20} = -150$ (*c* 0.04, CHCl₃)

Source of chirality: (1*R*,2*S*,5*R*)-menthol

Absolute configuration: (1*R*,2*S*,5*R*)




(α *R*,3*a**R*,9*b**R*)-5-Carbethoxy-1-(1-phenyl-2-hydroxyethyl)-7,8,9-trimethoxy-1,3*a*,4,9*b*-tetrahydro-3*H*-isoxazolo[4,3-*c*]quinoline

$[\alpha]_D^{23} = -19.5$ (*c* 0.7, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (α *R*,3*a**R*,9*b**R*)




(α *R*,3*a**S*,9*b**S*)-5-Carbethoxy-1-(1-phenyl-2-hydroxyethyl)-7,8,9-trimethoxy-1,3*a*,4,9*b*-tetrahydro-3*H*-isoxazolo[4,3-*c*]quinoline

$[\alpha]_D^{23} = -63.5$ (*c* 1.0, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (α *R*,3*a**S*,9*b**S*)




(α *R*,3*a**R*,9*b**R*)-5-Carbethoxy-1-(1-phenyl-2-hydroxyethyl)-7-methoxy-8-methyl-1,3*a*,4,9*b*-tetrahydro-3*H*-isoxazolo[4,3-*c*]quinoline

$[\alpha]_D^{23} = -11.1$ (*c* 0.9, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (α *R*,3*a**R*,9*b**R*)





(α R,3aS,9bS)-5-Carbethoxy-1-(1-phenyl-2-hydroxyethyl)-7-methoxy-8-methyl-1,3a,4,9b-tetrahydro-3H-isoxazolo[4,3-c]quinoline

$[\alpha]_D^{23} = -9.3$ (*c* 0.8, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydr-oxyamine

Absolute configuration: (α R,3aS,9bS)





(α R,3aR,9bR)-5-Carbethoxy-1-(1-phenyl-2-hydroxyethyl)-1,3a,4,10b-tetrahydro-3H,8H-[1,3]dioxolo[4,5-g]isoxazolo[4,3-c]quinoline

$[\alpha]_D^{23} = -7.9$ (*c* 1.0, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydr-oxyamine

Absolute configuration: (α R,3aR,10bR)





(α R,3aS,9bS)-5-Carbethoxy-1-(1-phenyl-2-hydroxyethyl)-1,3a,4,10b-tetrahydro-3H,8H-[1,3]dioxolo[4,5-g]isoxazolo[4,3-c]quinoline

$[\alpha]_D^{23} = -7.4$ (*c* 1.1, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydr-oxyamine

Absolute configuration: (α R,3aS,10bS)




(3R,4R)-4-Amino-1-carbethoxy-3-hydroxymethyl-5,6,7-trimethoxy-1,2,3,4-tetrahydroquinoline

$[\alpha]_D^{23} = +23.3$ (*c* 1.3, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydr-oxyamine

Absolute configuration: (3R,4R)




(3S,4S)-4-Amino-1-carbethoxy-3-hydroxymethyl-5,6,7-trimethoxy-1,2,3,4-tetrahydroquinoline

$[\alpha]_D^{23} = -22.9$ (*c* 1.1, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (3*S*,4*S*)




(3*R*,4*R*)-4-Amino-1-carbethoxy-3-hydroxymethyl-7-methoxy-6-methyl-1,2,3,4-tetrahydroquinoline

$[\alpha]_D^{23} = +29.3$ (*c* 0.6, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (3*R*,4*R*)




(3*S*,4*S*)-4-Amino-1-carbethoxy-3-hydroxymethyl-7-methoxy-6-methyl-1,2,3,4-tetrahydroquinoline

$[\alpha]_D^{23} = -29.9$ (*c* 0.5, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (3*S*,4*S*)




(7*R*,8*R*)-8-Amino-5-carbethoxy-7-hydroxymethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,3-*c*]quinoline

$[\alpha]_D^{23} = +25.9$ (*c* 0.6, CHCl₃)

Source of chirality: (*R*)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (7*R*,8*R*)




C₁₄H₁₈N₂O₅

(7S,8S)-8-Amino-5-carbethoxy-7-hydroxymethyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,3-c]quinoline

[α]_D²³ = -25.1 (c 0.5, CHCl₃)

Source of chirality: (R)-1-phenyl-2-hydroxyethylhydroxylamine

Absolute configuration: (7R,8R)




C₁₄H₁₉F₃O₉S

2,3:5,6-Di-O-isopropylidene-2-C-trifluoromethanesulfonyloxymethyl-D-mannono-1,4-lactone

Ee = 100%

[α]_D²¹ = +22.2 (c 1.0, CHCl₃)

Source of chirality: D-fructose as starting material




C₁₃H₁₉IO₆

2,3:5,6-Di-O-isopropylidene-2-C-iodomethyl-D-mannono-1,4-lactone

Ee = 100%

[α]_D²² = +31.8 (c 1.1, CHCl₃)

Source of chirality: D-fructose as starting material



C₁₃H₂₀O₆

2,3:5,6-Di-O-isopropylidene-2-C-methyl-D-mannono-1,4-lactone


Ee = 100%

[α]_D²² = +48.8 (c 0.9, CHCl₃)

Source of chirality: D-fructose as starting material

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

$[\alpha]_D^{22} = -130$ (*c* 0.7, CHCl₃)


Source of chirality: D-fructose as starting material



2-C-Azidomethyl-2,3:5,6-di-O-isopropylidene-D-mannono-1,4-lactone

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

$[\alpha]_D^{21} = -39$ (*c* 1.0, CHCl₃)


Source of chirality: D-fructose as starting material



2-C-Azidomethyl-2,3:5,6-di-O-isopropylidene-D-mannofuranose

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

$[\alpha]_D^{21} = +11.5$ (*c* 1.0, MeOH)


Source of chirality: D-fructose as starting material



2,3:5,6-Di-O-isopropylidene-2-C-hydroxymethyl-D-mannofuranose

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

$[\alpha]_D^{22} = +15.1$ (*c* 1.0, H₂O)


Source of chirality: D-fructose as starting material



2-C-Methyl-D-mannopyranose

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
 Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
 George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

[α]_D²² = +27.4 (c 1.0, H₂O)


Source of chirality: D-fructose as starting material

C₇H₁₄O₇

2-C-Hydroxymethyl-D-mannopyranose

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
 Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
 George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

[α]_D²³ = +41.0 (c 1.0, H₂O)


Source of chirality: D-fructose as starting material

C₇H₁₃N₃O₆

2-C-Azidomethyl-D-mannopyranose

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
 Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
 George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502



Ee = 100%

[α]_D²² = +3.7 (c 1.0, H₂O)


Source of chirality: D-fructose as starting material

C₇H₁₅NO₆

2-C-Aminomethyl-D-mannopyranose

Daniel A. Mitchell, Nigel A. Jones, Stuart J. Hunter, Joseph M. D. Cook,
 Sarah F. Jenkinson, Mark R. Wormald, Raymond A. Dwek and
 George W. J. Fleet*

Tetrahedron: Asymmetry 18 (2007) 1502




Ee = 100%

[α]_D²⁵ = +14.2 (c 0.85, MeOH)

Source of chirality: D-fructose as starting material

C₇H₁₁N₃O₆

2-C-Azidomethyl-D-mannono-1,4-lactone



Ee = 100%

$[\alpha]_D^{21} = +10.0$ (*c* 0.65, MeOH)

Source of chirality: D-fructose as starting material

C₇H₁₂O₇

2-C-Hydroxymethyl-D-mannono-1,4-lactone